Alzheimer’s research · Neurology · 2026
Summary: 73.5% of Alzheimer drug trials used lab tests or brain scans. Same paper’s results: 56.3%.
Share of the 238 Alzheimer drug trials using each kind of measure
The paper says
A paper that reviewed 238 Alzheimer drug trials says in its summary (the overview at the top) that 175 of them (73.5%) used at least one lab test or brain scan to check whether the drug worked, not only symptom tests such as memory quizzes.
Its own data show
The detailed results further down count the same thing and get 134 of 238 (56.3%). The paper’s separate counts for trials at earlier and later stages of testing also add up to 134 (79 + 55). The summary’s 175 is exactly another line of those results: trials using a symptom test as a main measure.
A trial’s main measures are the one or few results chosen to decide whether the drug worked; it can track other tests on the side. Many readers see only the summary, and a website summarising this paper already repeats its 73.5%: 41 trials (175 − 134) above the detailed count, about three in four instead of just over half.